The Kala Pharmaceuticals, Inc. (KALA) Reaches New 52-Week Low at $15.70

The Kala Pharmaceuticals, Inc. (KALA) Reaches New 52-Week Low at $15.70

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) hit a new 52-week low during trading on Thursday . The stock traded as low as $15.70 and last traded at $15.65, with a volume of 84,587 shares traded. The stock had previously closed at $16.50.

Several equities research analysts have recently commented on the company. Bank of America Corporation assumed coverage on Kala Pharmaceuticals in a research note on Monday, August 14th. They set a “buy” rating and a $33.00 price target on the stock. Wells Fargo & Company assumed coverage on Kala Pharmaceuticals in a research note on Monday, August 14th. They set an “outperform” rating and a $24.00 price target on the stock. J P Morgan Chase & Co began coverage on Kala Pharmaceuticals in a research note on Monday, August 14th. They set an “overweight” rating and a $35.00 price target on the stock. Oppenheimer Holdings, Inc. began coverage on Kala Pharmaceuticals in a research note on Tuesday, August 15th. They issued an “outperform” rating and a $46.00 target price on the stock. Finally, Wedbush began coverage on Kala Pharmaceuticals in a research note on Monday, August 14th. They issued an “outperform” rating and a $46.00 target price on the stock. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $36.80.

The stock’s 50 day moving average price is $22.00 and its 200-day moving average price is $21.56. The company’s market cap is $373.94 million.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Related posts

Leave a Comment